Neuro-Oncology · 2018 · 79 citations · 39 references
MedicineImmunologyOncologyCancer ImmunologyTumor ImmunologyTumor MicroenvironmentGlioblastomaMacrophage BiologyOncolytic Virus TherapyTumor Immune MicroenvironmentTumor Microenvironment ModulationTumor-associated MacrophagesCancer-associated MacrophagesGlioblastoma Oncolytic VirotherapyGlioblastoma Therapeutic ResistanceGlioblastoma Tumor MicroenvironmentM1 Macrophage PhenotypesMonocyte-derived MacrophagesOncolytic Viral TherapyOncolytic Virus - Mediated Microenvironment Modulation
Background: Immunosuppressive protumoral M2 macrophages are important in pathogenesis, progression, and therapy resistance in glioblastoma (GBM) and provide a target for therapy. Recently oncolytic virotherapy in murine models was shown to change these M2 macrophages toward the pro-inflammatory and antitumoral M1 phenotype. Here we study the effects of the oncolytic virotherapy Delta24-RGD in humans, using both in vitro models and patient material. Methods: Human monocyte-derived macrophages were co-cultured with Delta24-RGD-infected primary glioma stem-like cells (GSCs) and were analyzed for their immunophenotype, cytokine expression, and secretion profiles. Cerebrospinal fluid (CSF) from 18 Delta24-RGD-treated patients was analyzed for inflammatory cytokine levels, and the effects of these CSF samples on macrophage phenotype in vitro were determined. In addition, tumor macrophages in resected material from a Delta24-RGD-treated GBM patient were compared with 5 control GBM patient samples by flow cytometry. Results: Human monocyte-derived M2 macrophages co-cultured with Delta24-RGD-infected GSCs shifted toward an M1-immunophenotype, coinciding with pro-inflammatory gene expression and cytokine production. This phenotypic switch was induced by the concerted effects of a change in tumor-produced soluble factors and the presence of viral particles. CSF samples from Delta24-RGD-treated GBM patients revealed cytokine levels indicative of a pro-inflammatory microenvironment. Furthermore, tumoral macrophages in a Delta24-RGD-treated patient showed significantly greater M1 characteristics than in control GBM tissue. Conclusion: Together these in vitro and patient studies demonstrate that local Delta24-RGD therapy may provide a therapeutic tool to promote a prolonged shift in the protumoral M2 macrophages toward M1 in human GBM, inducing a pro-inflammatory and potentially tumor-detrimental microenvironment.
39
Roger Stupp, Monika E. Hegi, Warren Mason et al. · The Lancet Oncology · 2009 · 7.8K citations
Macrophage Activation and Polarization: Nomenclature and Experimental Guidelines
Peter J. Murray, Judith E. Allen, Subhra K. Biswas et al. · Immunity · 2014 · 6.2K citations · Full text
Jeongwu Lee, Svetlana Kotliarova, Yuri Kotliarov et al. · Cancer Cell · 2006 · 2.3K citations · Full text
Medicine, Cell Biology, Oncology +16
The cellular and molecular origin of tumor-associated macrophages
Ruth A. Franklin, Will Liao, Abira Sarkar et al. · Science · 2014 · 1.4K citations · Full text
Life Sciences, Immunology, Oncology +16